Amy J. Johnson, Ph.D.
Project Involvement: Project 6 - Pharmacology
Amy Johnson earned her PhD in Pharmaceutical Sciences from the University of Kentucky, studying the effects of cyclooxygenase-2 inhibitors on apoptosis pathways under the mentorship of Dr. Ching-Shih Chen.
Amy joined the Byrd Lab in 2002 as a post-doctoral researcher, examining the effects of OSU03012, a celecoxib derivative, on primary CLL cells. She also began the development and characterization of the Tcl-1 transgenic mouse model, an important tool for pre-clinical investigation of new therapeutic compounds. Amy was promoted to the position of Research Scientist in 2005, and again to Research Assistant Professor in 2007.
Amy currently leads multiple exciting research projects. Her research team has ongoing studies examining PI3-kinase/AKT inhibitors, HSP90 inhibitors, lenalidomide, and flavopiridol in the treatment of CLL.
- Chronic Lymphocytic Leukemia
- B Cell Receptor Signaling including PI3-kinase